[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Yokoyama Y, Moriya T, Takano T, Shoji T, Takahashi O, Nakahara K, Yamada H, Yaegashi N, Okamura K, Izutsu T, Sugiyama T, Tanaka T, Kurachi H, Sato A, Tase T, Mizunuma H: Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer; 2006 Jun 5;94(11):1586-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred and twenty-one borderline ovarian tumours treated between 1994 and 2003 at the participating institutions in the Tohoku Gynecologic Cancer Unit were retrospectively investigated for clinical stage, histopathological subtype, surgical technique, postoperative chemotherapy, the presence or absence of recurrence, and prognosis.
  • The histopathological subtypes consisted of 91 cases of mucinous tumour (75.2%), 27 cases of serous tumour (22.3%), and three cases of endometrioid tumour.
  • Conservative surgery was used in 53 cases (43.8%), radical surgery in 68 cases (56.2%), a staging laparotomy in 43 cases (35.5%), and postoperative adjuvant therapy in 30 cases (24.8%).
  • Recurrence was found in eight cases, but no tumour-related deaths were reported.
  • Although no significant difference in disease-free survival rate was seen between different clinical stages, the difference in disease-free survival rate between serous and non-serous (mucinous and endometrioid) types was significant (P<0.05).
  • In the conservative surgery group, cystectomy and serous tumour were independent risk factors for recurrence.
  • Although recurrence was observed, the long-term prognosis of borderline ovarian tumour was favourable, without tumour-related deaths.
  • Considering the favourable prognosis, conservative surgery can be chosen as far as the patient has a non-serous tumour and receive adnexectomy.
  • However, in cases of serous type and/or receiving cystectomy special care should be given as relative risk rates of recurrence elevate by 2-4-folds.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4053-8 [10632339.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jan;156(1):263-4 [10681275.001]
  • [Cites] Obstet Gynecol. 2000 Apr;95(4):541-7 [10725486.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):69-75 [10883027.001]
  • [Cites] Fertil Steril. 2001 Jan;75(1):92-6 [11163822.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2658-64 [11352957.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):332-8 [12229940.001]
  • [Cites] Obstet Gynecol. 2002 Oct;100(4):671-6 [12383532.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):29-36 [12496695.001]
  • [Cites] Fertil Steril. 2003 May;79(5):1216-21 [12738521.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1045-52 [14983501.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):934-48 [15297961.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):949-60 [15297962.001]
  • [Cites] Obstet Gynecol. 1986 Sep;68(3):338-44 [3737056.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2212-22 [3179935.001]
  • [Cites] Cancer. 1992 Jul 1;70(1):152-60 [1606537.001]
  • [Cites] Am J Epidemiol. 1992 Nov 15;136(10):1204-11 [1476142.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1810-20 [8383580.001]
  • [Cites] Gynecol Oncol. 1995 Dec;59(3):390-3 [8522261.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • (PMID = 16685277.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361313
  •  go-up   go-down


2. Kupryjańczyk J, Dansonka-Mieszkowska A, Szymańska T, Karpińska G, Rembiszewska A, Rusin M, Konopiński R, Kraszewska E, Timorek A, Yandell DW, Stelmachów J: Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction. Br J Cancer; 2000 Feb;82(3):579-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in cell survival contribute to tumour development, influence tumour biology and its response to chemotherapy. p53 gene alterations should negatively affect apoptosis by impaired p53-dependent apoptotic response.
  • The AI was negatively associated with good histological differentiation (P = 0.0006), the serous tumour type (P = 0.002), and diffuse bcl-2 expression (P = 0.025).
  • Strong bcl-2 expression was associated with endometrioid tumour type (P = 0.002).
  • FIGO stage and p53 protein accumulation were the only parameters that influenced overall survival time.
  • Thus, our results suggest that histological tumour type and grade are major determinants of spontaneous apoptosis in ovarian carcinomas; p53 alterations do not adversely but rather positively affect spontaneous apoptosis by increasing growth fraction.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Genes, bcl-2. Humans. Middle Aged. Survival Analysis


3. Kupryjańczyk J, Szymańska T, Madry R, Timorek A, Stelmachów J, Karpińska G, Rembiszewska A, Ziółkowska I, Kraszewska E, Debniak J, Emerich J, Ułańska M, Płuzańska A, Jedryka M, Goluda M, Chudecka-Głaz A, Rzepka-Górska I, Klimek M, Urbański K, Breborowicz J, Zieliński J, Markowska J: Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer; 2003 Mar 24;88(6):848-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In cell line studies, BCL-2, BAX, as well as novel MEK1 protein levels have strong influence on ovarian cancer response to cisplatin-based chemotherapy.
  • Immunohistochemical analysis was performed on 229 ovarian carcinomas FIGO stage IIB-IV treated with platinum-based chemotherapy; the results were analysed by the Cox and logistic regression models.
  • Clinical parameters (residual tumour size, patient age, FIGO stage) were the only indicators of overall survival (OS) and the strongest predictors of complete remission (CR).
  • High MEK1 expression was associated with endometrioid and clear cell carcinomas (P=0.049); its loss was found with advancing FIGO stage (P=0.002).
  • BCL-2 and BAX, but not MEK1 expressions have predictive value in ovarian cancer patients treated with platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Gene Expression Regulation, Neoplastic. Mitogen-Activated Protein Kinase Kinases / biosynthesis. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / genetics. Protein-Serine-Threonine Kinases / biosynthesis. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Female. Humans. Immunohistochemistry. MAP Kinase Kinase 1. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Regression Analysis. Treatment Outcome. bcl-2-Associated X Protein

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2984-97 [11595686.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2178-84 [8616869.001]
  • [Cites] Am J Obstet Gynecol. 1975 Mar 15;121(6):795-807 [1092171.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5 [8506342.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):64-9 [8270986.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1799-805 [8183579.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 2):S143-50 [7835799.001]
  • [Cites] Gynecol Oncol. 1995 Feb;56(2):175-80 [7896181.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1217-28 [7478541.001]
  • [Cites] Am J Clin Pathol. 1996 Mar;105(3):341-9 [8602616.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2061 [10561259.001]
  • [Cites] Br J Cancer. 1999 Oct;81(4):733-40 [10574264.001]
  • [Cites] Eur J Cancer. 1999 Aug;35(8):1214-9 [10615232.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):436-40 [10646901.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):579-83 [10682669.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):2010-30 [10711243.001]
  • [Cites] Nature. 2000 Apr 20;404(6780):892-7 [10786798.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):278-82 [10785478.001]
  • [Cites] J Cell Biochem. 2000 Sep 7;79(3):355-69 [10972974.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):689-93 [8630996.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2236-46 [8918420.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1971-81 [8934544.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3C):2233-40 [9216694.001]
  • [Cites] Br J Cancer. 1997;76(4):474-9 [9275024.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):892-8 [9307189.001]
  • [Cites] Mol Pharmacol. 1998 May;53(5):819-26 [9584207.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7439-44 [9636168.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Sep;105(2):93-102 [9723023.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jan;18(1):29-41 [9891239.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 1:9-15 [10219447.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2847-52 [10383145.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1869-75 [10974636.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):2006-17 [11064359.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3775-81 [11078490.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3936-45 [11099323.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39435-43 [10993883.001]
  • [Cites] Oncogene. 2000 Dec 14;19(54):6216-28 [11175336.001]
  • [Cites] J Pathol. 2001 May;194(1):68-75 [11329143.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2317-28 [11094305.001]
  • [Cites] Br J Cancer. 2001 Nov 2;85(9):1359-67 [11720475.001]
  • (PMID = 12644821.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; EC 2.7.1.- / MAP2K1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2377076
  •  go-up   go-down


Advertisement
4. Zepiridis L, Zafrakas M, Theodoridis TD, Kaplanis K, Dinas KK, Bontis JN: A unique case of palatinate tonsil metastasis from endometrial cancer. Eur J Gynaecol Oncol; 2009;30(2):229-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastases from malignancies of the female genital tract to the tonsils have never been reported.
  • A case of a 55-year-old woman presenting with a palatinate tonsil tumour two and half years after primary diagnosis of endometrioid endometrial adenocarcinoma (FIGO Stage IB, G2) and six months after local disease recurrence is presented.
  • The tonsillar malignancy was poorly differentiated and tumour cells were immunohistochemically positive to LMW keratin and EMA, and negative to HMW keratin and LCA, strongly suggesting a possible endometrial origin of the tumour.
  • Metastatic disease was treated with systemic chemotherapy, but the patient soon succumbed due to rapid disease progression.
  • In conclusion, a unique case of a palatinate tonsil tumour as the first metastatic site in an endometrial cancer patient is reported.
  • [MeSH-minor] Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480265.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Obeidat B, Latimer J, Crawford R: Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Invest; 2004;57(3):153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A receiver operating characteristic (ROC) curve was used to determine the most useful CA-125 level in predicting optimal versus suboptimal tumour cytoreduction.
  • Optimal cytoreduction was obtained in 16 of the 21 cases (76%) with a CA-125 <500 U/ml compared to only 6 of the 19 cases (32%) with a CA-125 >500 U/ml.
  • At this threshold, preoperative serum CA-125 level was able to predict optimal versus suboptimal cytoreduction with a sensitivity of 72%, specificity of 73%, positive predictive value of 68%, and negative predictive value of 76%.
  • In the management of patients with advanced epithelial ovarian carcinoma, preoperative serum CA-125 level may help to predict optimal primary cytoreduction and to identify candidates for alternative approaches other than traditional primary cytoreductive surgery, such as neoadjuvant chemotherapy.
  • [MeSH-major] CA-125 Antigen / blood. Ovarian Neoplasms / surgery. Treatment Outcome
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / surgery. Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / surgery. Cystadenocarcinoma, Papillary / blood. Cystadenocarcinoma, Papillary / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Preoperative Care. Retrospective Studies. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 14726621.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


6. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • Serum CA125 level was found to be elevated in 22 of the 34 examined cases (64.7%) with a median value of 500 U/ml (range, 39-3439 U/ml).
  • The predominant ovarian histology was endometrioid or mixed tumor with endometrioid components (30/43, 69.8%).
  • Postoperatively, 26 patients (60.5%) received adjuvant chemotherapy alone, 12 had chemotherapy plus radiotherapy, only one patient had radiation alone and the remaining 4 cases received no adjuvant treatment.
  • The 3- and 5-year survival rates of patients with both endometrioid and ovarian carcinomas were higher than that of those with non-endometrioid or mixed subtypes (93.8%, 82.0% vs. 79.7%, 69.0%).
  • Recurrence developed in 15 patients (34.9%).
  • It was showed by univariate analysis that lower CA125 level, early FIGO stage, and adjuvant chemotherapy plus radiotherapy significantly and positively affect the 5-year survival rates, while only early FIGO stage and chemotherapy plus radiotherapy were revealed by multivariate analysis as independent prognostic factors.
  • CONCLUSION: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis.
  • Surgical treatment alone may be enough for early stage patients.
  • Chemotherapy plus radiotherapy may be necessary for advanced stage patients.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Hysterectomy / methods. Neoplasms, Multiple Primary. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Proteins / metabolism. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


7. Polverino G, Parazzini F, Stellato G, Scarfone G, Cipriani S, Bolis G: Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. Gynecol Oncol; 2005 Nov;99(2):343-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy.
  • OBJECTIVE: We evaluated the characteristics and determinants of 5-year survival in ovarian cancer patients with complete response after first line treatment who entered a randomised study comparing two different chemotherapeutic schedules.
  • METHODS: This analysis included 232 ovarian cancer patients with complete response after first line surgery and chemotherapy coming from a large randomised trial comparing the effect of different doses of paclitaxel combined with fixed doses of carboplatin.
  • Serous and clear cell histotypes had a worse 5-year overall survival (51.5% and 50.8% respectively), while the endometrioid and mucinous had 67.1% and 71.4%: these differences were statistically different (P = 0.04).
  • Women with residual tumour of 1 cm or smaller after primary surgery had better 5-year survival rates: 71.2% for patients with residual tumour < or = 1 cm and 46.9% for residual tumour >1 cm: these differences were statistically significant (P < 0.006).
  • CONCLUSION: This study shows that in women with ovarian cancer and complete response after first line surgery and chemotherapy, age, histotype and residual tumour after surgery are determinants of 5-year overall survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051334.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Bar JK, Harłozińska A, Popiela A, Noga L: Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy. Tumour Biol; 2001 Mar-Apr;22(2):83-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
  • p53 alterations are considered as one of the most important factors responsible for drug resistance in ovarian carcinomas, although the relationship between p53 gene status and response to cisplatin-based chemotherapy in ovarian cancer patients remains unclear.
  • The aim of the study was to evaluate the relationship between p53 protein accumulation, p53 gene mutation and response to cisplatin-based chemotherapy in patients with ovarian carcinoma considering conventional clinicopathological parameters.
  • Tissue sections and corresponding cyst and/or ascitic fluid cells from 79 patients with epithelial ovarian cancer were analyzed immunohistochemically for p53 expression.
  • It was demonstrated that p53 expression reaching approximately 50% of positive cells in immunostaining was usually associated with PCR-amplified exons showing abnormal migration and suspected for mutation. p53 gene changes were not correlated with histological structure, grade of differentiation or residual tumor after cytoreductive surgery, despite being detected more frequently in III/IV than in II FIGO stages and in patients with residual disease above 2 cm.
  • A significant correlation between p53 accumulation and p53 gene alteration and poor response to cisplatin-based chemotherapy was shown.
  • The overall survival time of patients decreased with an increase in p53 protein expression.
  • A strong p53 expression especially accompanied by p53 changes detectable by PCR-SSCP analysis appears to be a good indicator of the resistance to cisplatin-based chemotherapy.
  • The association between strong p53 overexpression and shorter overall survival time was also revealed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma / genetics. Carcinoma / metabolism. Cisplatin / therapeutic use. Genes, p53. Mutation. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / mortality. Ascites / metabolism. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / mortality. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / mortality. DNA Mutational Analysis. Exons. Female. Humans. Immunohistochemistry. Polymorphism, Single-Stranded Conformational. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11125280.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Popadiuk CM, Xiong J, Wells MG, Andrews PG, Dankwa K, Hirasawa K, Lake BB, Kao KR: Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clin Cancer Res; 2006 Apr 1;12(7 Pt 1):2216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In epithelial ovarian cancer, constitutively active Wnt signaling is restricted to one (endometrioid) tumor subtype.
  • Depletion of hPygo2 by antisense oligonucleotides in both Wnt-active (TOV-112D) and Wnt-inactive serous (OVCAR-3, SKOV-3) and clear cell (TOV-21G) carcinoma cell lines halted growth, assessed using tissue culture, anchorage-independent, and xenograft assays.
  • These findings strongly suggest that inhibition of hPygo2 may be of therapeutic benefit for treating this disease.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / drug effects. Neoplasms, Glandular and Epithelial / drug therapy. Oligodeoxyribonucleotides, Antisense / pharmacology. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Drug Screening Assays, Antitumor. Female. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. In Vitro Techniques. Mice. Neoplasms, Experimental / therapy. Structure-Activity Relationship. Transplantation, Heterologous. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609037.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / PYGO2 protein, human
  •  go-up   go-down


10. Sufliarsky J, Chovanec J, Svetlovska D, Minarik T, Packan T, Kroslakova D, Lalabova R, Helpianska L, Horvathova D, Sevcik L, Spacek J, Laluha A, Tkacova V, Malec V, Rakicka G, Magdin D, Jancokova I, Dorr A, Stresko M, Habetinek V, Koza I: Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer. Neoplasma; 2009;56(4):291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
  • Despite progress in primary treatment of patients with advanced ovarian cancer, the majority develop recurrence of the disease.
  • A platinum salt treatment, either as monotherapy or in combination with another cytostatic agent, is indicated for patients who have relapsed 6 or more months after primary treatment and thus have platinum-sensitive relapse.
  • Because repeated use of paclitaxel treatment may lead to substantial neurotoxicity, the combination of gemcitabine with carboplatin represents a suitable treatment option, which is widely used in common clinical practice in the Czech Republic and Slovakia.
  • This non-interventional, prospective study observed the effectiveness and tolerability of second-line treatment with gemcitabine and carboplatin in patients with platinum-sensitive relapse of ovarian cancer in routine clinical practice.
  • The primary endpoint was to evaluate the survival and secondary endpoints were to evaluate time to disease progression, objective tumor response rate, and treatment toxicity.
  • Patients were enrolled to planned second-line treatment with gemcitabine and carboplatin (gemcitabine 1000 mg/m2 and carboplatin AUC 5 on Day 1, and gemcitabine 1000 mg/m2 on Day 8 of a 21-day cycle) for platinum-sensitive relapse of ovarian cancer as a part of routine clinical practice and followed for 12 months.
  • The events (death, tumor progression), tumor response, and maximal grades of toxicity were recorded according to common clinical practice.
  • Survival time (using Kaplan-Meier analysis) and objective tumor response rate were calculated using data forms, and a subgroup analysis was performed using log rank tests for time-to-event endpoints; p-values were also calculated.
  • Approximately 91% of patients were originally diagnosed with stage III or IV; 60% of patients had disease free intervals (DFIs) of 12 or more months from previous therapy, and the additional 40% less than 12 months.
  • Median survival time was not determined within the 12-month period following the start of the treatment study due to the limited duration of follow-up.
  • Objective tumour response rate was 67.3%.
  • Most common reasons for discontinuation of therapy were "Planned treatment completed" (53%) and "Tumor progression" (11%).
  • Most common toxicities were leukopenia, anaemia, neutropenia, and thrombocytopenia; grades 3 and 4 of these toxicity types did not exceed 30%.
  • Results on time to disease progression are not published due to inconsistent statistical analysis of reported data.
  • Based on this observation from routine clinical practice, which corresponds with previously published results from controlled clinical trials, the gemcitabine and carboplatin combination seems to be a suitable therapeutic option for patients with platinum-sensitive relapse of ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / secondary. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473054.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


11. Jeschke U, Mylonas I, Kunert-Keil C, Stahn R, Scholz C, Janni W, Kuhn C, Schröder E, Mayr D, Friese K: Immunohistochemistry, glycosylation and immunosuppression of glycodelin in human ovarian cancer. Histochem Cell Biol; 2009 Feb;131(2):283-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glycodelins (Gds) are glycoproteins with a gender specific glycosylation.
  • Glycodelin A (GdA) is primarily produced in endometrial and decidual tissue and secreted to amniotic fluid.
  • Glycodelins were also identified in several cancer types, including serous ovarian cancer.
  • Gds act as a T-cell inhibitor and are involved in inactivation of human monocytes.
  • With a Gd peptide antibody, derived from a 15 amino acid sequence of human Gd and in situ hybridization experiments, the expression of Gd in serous, mucinous, endometrioid and clear cell ovarian tumors was identified.
  • Ascites Gd showed significant differences in its structure of sialyl Lewis-type oligosaccharides compared to GdA.
  • [MeSH-minor] Cell Adhesion / drug effects. Female. Glycodelin. Glycosylation. Humans. Immunohistochemistry. Immunosuppression. Lymphocyte Activation / drug effects. Oligosaccharides / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Reprod Immunol. 1991 Dec;26(4):137-42 [1840727.001]
  • [Cites] Glycobiology. 1998 Nov;8(11):1053-64 [9751792.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1435-43 [8623915.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23 (2A):1119-25 [12820358.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):569-76 [9472094.001]
  • [Cites] J Perinat Med. 2005;33(3):212-8 [15914343.001]
  • [Cites] Virchows Arch. 2005 Apr;446(4):360-8 [15756591.001]
  • [Cites] Biol Reprod. 2003 Nov;69(5):1545-51 [12826581.001]
  • [Cites] Arch Gynecol Obstet. 2003 Aug;268(3):162-7 [12942243.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(1):17-25 [16807671.001]
  • [Cites] Vopr Onkol. 1990;36(7):845-9 [2205044.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):173-9 [11437921.001]
  • [Cites] Endocrinology. 2007 Feb;148(2):896-902 [17068141.001]
  • [Cites] Mol Hum Reprod. 1996 Oct;2(10 ):759-65 [9239694.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):24116-26 [7592613.001]
  • [Cites] Cell Immunol. 2003 Apr;222(2):156-63 [12826085.001]
  • [Cites] Fertil Steril. 1998 Mar;69(3):543-8 [9531894.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23 ):8845-9 [3194393.001]
  • [Cites] Gynecol Obstet Invest. 2004;58(4):207-11 [15297810.001]
  • [Cites] J Biol Chem. 1985 Oct 25;260(24):12957-67 [3863814.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5201-6 [9393734.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13789-94 [12370411.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98 (16):9265-70 [11459932.001]
  • [Cites] Arch Androl. 1984;12 Suppl:59-67 [6398989.001]
  • [Cites] Endocrinology. 1986 May;118(5):1782-6 [3516653.001]
  • [Cites] Z Geburtshilfe Neonatol. 2005 Apr;209(2):59-64 [15852231.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1581-9 [16033064.001]
  • [Cites] Fertil Steril. 1995 Feb;63(2):377-83 [7531163.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Clin Exp Immunol. 1989 Aug;77(2):252-6 [2789118.001]
  • [Cites] Blood. 1994 Jul 15;84(2):467-73 [8025274.001]
  • [Cites] Histochem Cell Biol. 2003 May;119(5):345-54 [12743827.001]
  • [Cites] Glycobiology. 1994 Apr;4(2):221-5 [7519910.001]
  • [Cites] J Immunol Methods. 1991 Jan 24;136(1):85-90 [1995715.001]
  • [Cites] J Reprod Immunol. 1988 Jun;13(1):31-9 [3418616.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28268-73 [11325960.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14059-65 [12556471.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1639-44 [16033074.001]
  • [Cites] J Mol Endocrinol. 1999 Aug;23 (1):57-66 [10425447.001]
  • [Cites] Acta Endocrinol (Copenh). 1986 Jun;112(2):271-7 [3526786.001]
  • [Cites] Cells Tissues Organs. 2001;168(1-2):113-21 [11114593.001]
  • [Cites] J Clin Endocrinol Metab. 1981 May;52(5):1006-8 [7014586.001]
  • [Cites] Fertil Steril. 2006 Nov;86(5):1488-97 [17070198.001]
  • [Cites] Placenta Suppl. 1982;4:67-81 [6085895.001]
  • [Cites] J Mol Histol. 2005 Feb;36(1-2):111-7 [15704005.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(4):165-9 [8844133.001]
  • [Cites] Endocr Rev. 2002 Aug;23 (4):401-30 [12202458.001]
  • [Cites] Cell Immunol. 1999 Jan 10;191(1):26-33 [9918684.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):738-42 [10597188.001]
  • [Cites] Histochem Cell Biol. 2005 Jun;123(6):631-7 [15889266.001]
  • [Cites] Hum Reprod. 2007 Oct;22(10 ):2615-22 [17720699.001]
  • [Cites] J Reprod Fertil Suppl. 1988;36:127-41 [3057195.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):565-73 [9426393.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):2023-5 [17649816.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6258-64 [14559812.001]
  • [Cites] J Exp Med. 2003 Oct 20;198(8):1201-12 [14568979.001]
  • [Cites] Histochem Cell Biol. 2002 Mar;117(3):219-26 [11914919.001]
  • [Cites] Endocrinology. 2005 Dec;146(12 ):5365-73 [16123169.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17101-5 [11278680.001]
  • [Cites] Histochem Cell Biol. 2000 Nov;114(5):405-11 [11151410.001]
  • [Cites] Immunology. 1990 Feb;69(2):277-81 [2307483.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):32159-67 [8943270.001]
  • [Cites] EMBO J. 1999 Mar 15;18(6):1516-25 [10075923.001]
  • [Cites] Lancet. 1987 Mar 14;1(8533):593-5 [2881133.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):413-9 [15706409.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):296-300 [9221808.001]
  • [Cites] Glycobiology. 1998 Apr;8(4):311-19 [9499378.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;270:121-44 [12467248.001]
  • [Cites] Tumour Biol. 1992;13(3):175-9 [1626182.001]
  • (PMID = 18853174.001).
  • [ISSN] 1432-119X
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / Glycodelin; 0 / Glycoproteins; 0 / Oligosaccharides; 0 / PAEP protein, human; 0 / Pregnancy Proteins
  •  go-up   go-down


12. Fischer G, Odunsi K, Lele S, Mhawech P: Ovarian primary primitive neurectodermal tumor coexisting with endometrioid adenocarcinoma: a case report. Int J Gynecol Pathol; 2006 Apr;25(2):151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian primary primitive neurectodermal tumor coexisting with endometrioid adenocarcinoma: a case report.
  • We report an unusual case of a 78-year-old woman with primary ovarian tumor that consisted of primitive neurectodermal tumor and endometrioid adenocarcinoma.
  • She was treated with debulking surgery followed by chemotherapy.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Neoplasms, Multiple Primary. Neuroectodermal Tumors, Primitive. Ovarian Neoplasms
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633064.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. McCluggage WG, Lyness RW, Atkinson RJ, Dobbs SP, Harley I, McClelland HR, Price JH: Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol; 2002 Jan;55(1):27-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological effects of chemotherapy on ovarian carcinoma.
  • AIMS: Traditionally, advanced stage ovarian carcinoma is treated by debulking surgery followed by chemotherapy.
  • However, in some circumstances preoperative chemotherapy may be given before optimal surgical debulking.
  • This study aims to describe the morphological features found in ovarian carcinoma after chemotherapy because these have not been detailed previously.
  • METHODS: Histological sections were examined from 18 cases of ovarian carcinoma that had been treated by preoperative chemotherapy.
  • The morphology was compared with any pre-chemotherapy biopsies that had been performed.
  • Tumours were classified as showing morphological features suggesting a good response to chemotherapy (n = 14) or as showing little or no response (n = 4).
  • Serum CA125 values before and after chemotherapy were compared.
  • In all cases, the mitotic activity index (MAI), volume percentage of epithelium (VPE), and mean nuclear area (MNA) of tumour cells were calculated.
  • RESULTS: The preoperative biopsies were all typical ovarian serous or endometrioid adenocarcinomas.
  • Morphological features present in the group responding to chemotherapy included the presence of small groups or single tumour cells in a densely fibrotic stroma.
  • Tumour cells were characterised by both nuclear and cytoplasmic alteration, making accurate tumour typing and grading impossible.
  • In all nine cases in which pre-chemotherapy and post-chemotherapy biopsies were available, the MNA increased post-chemotherapy (p = 0.007, paired Wilcoxon test) and in six of nine cases the MAI decreased (p = 0.093).
  • CONCLUSIONS: Because preoperative chemotherapy is being used increasingly in the management of ovarian cancer, pathologists should be aware of the resultant morphological effects.
  • Accurate tumour typing and grading is impossible.
  • In some cases, it may be difficult to confirm the presence of residual tumour, making it imperative that pre-chemotherapy tissue biopsies are obtained.
  • Definite confirmation of residual tumour may require the examination of multiple histological sections from areas showing pronounced stromal changes, sometimes with multiple levels and immunohistochemistry.
  • In the absence of definite residual tumour, the report should state that the features are consistent with the prior presence of tumour.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Agents / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] CA-125 Antigen / blood. Cell Nucleus / pathology. Female. Humans. Mitotic Index. Neoadjuvant Therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Obstet Gynaecol. 1999 Nov;106(11):1130-6 [10549956.001]
  • [Cites] Histopathology. 1999 Dec;35(6):584-5 [10583584.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] J Clin Pathol. 2000 May;53(5):327-34 [10889812.001]
  • [Cites] Natl Cancer Inst Monogr. 1975 Oct;42:101-4 [1234624.001]
  • [Cites] Cancer. 1993 Dec 15;72(12):3663-70 [8252483.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):283-90 [10474521.001]
  • [Cites] Histopathology. 1996 Jul;29(1):63-7 [8818696.001]
  • [Cites] Lung Cancer. 1996 Sep;15(2):183-7 [8882984.001]
  • [Cites] Am J Clin Pathol. 1997 Feb;107(2):211-8 [9024070.001]
  • [Cites] Gynecol Oncol. 1998 Jul;70(1):2-12 [9698465.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] J Clin Pathol. 1996 Feb;49(2):142-8 [8655681.001]
  • (PMID = 11825920.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen
  • [Other-IDs] NLM/ PMC1769574
  •  go-up   go-down


14. Skirnisdóttir I, Seidal T, Gerdin E, Sorbe B: The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer; 2002 May-Jun;12(3):265-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
  • In a series of 109 patients with epithelial carcinomas in FIGO stages IA-IIC, a number of clinicopathologic prognostic factors (age, FIGO stage, histopathologic type, and tumor grade) were studied in relation to the biologic factors p53, bcl-2, and bax, which are important regulators of apoptosis.
  • All the patients received adjuvant chemotherapy after the primary surgery.
  • Univariate analysis showed that expression of p53 was significantly associated with tumor grade (P = 0.014), probability of persistent disease (P = 0.016), and cancer-specific survival rate (P = 0.007).
  • Positive bcl-2 staining was associated with endometrioid tumor subtype (P = 0.029) and a favorable tumor grade distribution (P = 0.034), but not with the survival status.
  • The combined p53-bcl-2 expression was related to histopathologic subtype (P = 0.032), tumor grade (P = 0.011), persistent disease (P = 0.014), and risk of dying due to the disease (P = 0.039).
  • The bax status was not a prognostic factor, but the combined p53-bax expression showed an association with FIGO stage (P = 0.014), tumor grade (P = 0.034), persistent disease (P = 0.006), and risk of dying due to the disease (P = 0.039).
  • The combined bcl-2-bax expression was related to histopathologic subtype (P = 0.045) and tumor grade (P = 0.022).
  • In a multivariate Cox analysis, tumor grade (P = 0.014), and p53 status (P = 0.020) were independent and significant prognostic factors with regard to the cancer-specific survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Aged, 80 and over. Carcinoma / drug therapy. Carcinoma / metabolism. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / metabolism. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Survival Rate. bcl-2-Associated X Protein

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060448.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Wu TI, Chang TC, Hsueh S, Lai CH: Ovarian endometrioid carcinoma with diffuse pigmented peritoneal keratin granulomas: a case report and review of the literature. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):426-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian endometrioid carcinoma with diffuse pigmented peritoneal keratin granulomas: a case report and review of the literature.
  • The presence of keratin granulomas in peritoneal cavity associated with ovarian endometrioid carcinoma, which might be related to leakage from the ovarian tumor, is rarely reported.
  • We report a case presenting with intermittent abdominal pain after an acute episode 1 month before a complex adnexal tumor was noted.
  • The ovarian tumor was an endometrioid adenocarcinoma with squamous differentiation.
  • Since viable epithelial cells in the implants could be differentially identified against mesothelial or granulomatous components by CK-7 staining and DNA aneuploidy was demonstrated on primary ovarian tumor, four courses of chemotherapy were administered.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Granuloma / pathology. Lymph Nodes / pathology. Ovarian Neoplasms / pathology. Peritoneal Diseases / pathology
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Biopsy, Needle. Female. Flow Cytometry. Follow-Up Studies. Frozen Sections. Humans. Immunohistochemistry. Laparotomy. Middle Aged. Ovariectomy. Treatment Outcome


16. Gadducci A, Cavazzana A, Cosio S, DI Cristofano C, Tana R, Fanucchi A, Teti G, Cristofani R, Genazzani AR: Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res; 2009 May;29(5):1715-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer.
  • The aim of this retrospective study was to assess the predictive value of different clinicopathological variables (patient age, tumour size, FIGO grade, myometrial invasion, lymph-vascular space involvement [LVSI], invasion margins, peri-tumour phlogistic infiltrate and mitotic activity) for the risk of distant haematogenous recurrences in patients with endometrioid-type stage Ib-II endometrial cancer.
  • Between August 1990 and April 2005, 259 patients had undergone laparotomy, peritoneal washing, total abdominal hysterectomy and bilateral salpingo-oophorectomy, with or without pelvic +/- para-aortic lymphadenectomy for endometrioid-type endometrial cancer.
  • Thirty-six (13.9%) patients had developed recurrent disease after a median time of 17 months (range, 2-128 months).
  • This study assessed 12 patients with FIGO stage Ib-II disease who had developed distant haematogenous recurrences and 20 randomly chosen control patients with FIGO stage Ib-II disease who had remained recurrence-free after a median follow-up of 52 months (range, 37-66 months).
  • Adjuvant therapy had been: no further treatment in 15 patients, external pelvic irradiation in 14 patients, adjuvant external pelvic irradiation plus brachytherapy in 2 patients and platinum-based chemotherapy followed by external pelvic irradiation in 1 patient.
  • % versus 20.0%, p=0.0022) was found in the patients who had developed distant haematogeneous metastases compared to the recurrence-free women.
  • Patients with these pathological findings should be enrolled in randomised trials designed to assess the role of adjuvant chemotherapy alone or combined with sequential and/or concomitant external pelvic irradiation.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Invasiveness. Recurrence. Retrospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443392.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


17. Powell JL, Connor GP, Henderson GS: Androgen-producing, atypically proliferating endometrioid tumor arising in endometriosis. South Med J; 2001 Apr;94(4):450-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen-producing, atypically proliferating endometrioid tumor arising in endometriosis.
  • A case of androgen-secreting borderline endometrioid tumor arising in endometriosis of the rectovaginal septum is presented.
  • We believe 7 years of unopposed continuous oral estrogen replacement therapy contributed to the malignant transformation of the endometriosis.
  • [MeSH-major] Androgens / secretion. Carcinoma, Endometrioid / complications. Carcinoma, Endometrioid / pathology. Endometriosis / complications. Rectal Neoplasms / complications. Rectal Neoplasms / pathology. Vaginal Neoplasms / complications. Vaginal Neoplasms / pathology
  • [MeSH-minor] Abdominal Pain / etiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic / drug effects. Combined Modality Therapy. Dyspareunia / etiology. Estrogen Replacement Therapy / adverse effects. Estrogen Replacement Therapy / methods. Female. Hirsutism / etiology. Humans. Hysterectomy. Middle Aged. Mitotic Index. Ovariectomy. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11332919.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens
  •  go-up   go-down


18. Clarke BA, Gilks CB: Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol; 2010 May;63(5):410-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type.
  • Histopathological assessment of tumour grade and cell type is central to the management of endometrial carcinoma, guiding the extent of surgery and the use of adjuvant radiation therapy and chemotherapy.
  • Endometrioid carcinomas are usually low grade but high-grade examples are encountered, and they have a significantly worse prognosis, similar to that of high-grade subtypes such as serous and clear cell carcinoma.
  • This article reviews the various grading systems that have been proposed for use with endometrioid endometrial carcinoma, and discusses the recent progress in cell type assignment, including the use of immunohistochemistry as a diagnostic adjunct.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418232.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 38
  •  go-up   go-down


19. Malinowski A, Augustyniak T, Bartosiak I, Maciołek-Bleniewska G, Ciesielski A: [Conservative treatment of ectopic pregnancy in a 27 years old patient with stage-Ia ovarian cancer after conservative surgical treatment and chemotherapy]. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):317-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conservative treatment of ectopic pregnancy in a 27 years old patient with stage-Ia ovarian cancer after conservative surgical treatment and chemotherapy].
  • [Transliterated title] Zachowawcze leczenie ciazy ektopowej u 27-letniej pacjentki z rakiem jajnika w stopniu Ia po oszczedzajacym leczeniu chirurgicznym i chemoterapii.
  • We report a case of conservative treatment of ectopic pregnancy in a 27 years old patient, previously treated for ovarian cancer.
  • Two years before she had surgery because of tumour in the left ovary.
  • Considering the patient s young age, future reproductive plans and the early stage of cancer, the patient qualified for conservative treatment.
  • Left adnexectomy with consequent chemotherapy (6 courses) was performed.
  • [MeSH-major] Abortifacient Agents, Nonsteroidal / administration & dosage. Carcinoma, Endometrioid / therapy. Methotrexate / administration & dosage. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy, Tubal / drug therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Female. Humans. Neoplasm Staging. Pregnancy. Time Factors. Treatment Outcome


20. Pan Y, Kao MS: Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review. Curr Oncol; 2010 Nov;17(6):82-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review.
  • Aromatase inhibitors have not been adequately assessed in treatment of ovarian cancer.
  • The aromatase inhibitor letrozole (2.5 mg daily) was administered in 2 cases of advanced endometrioid ovarian cancer with positive estrogen receptor.
  • CASE 1: A 52-year-old woman with a grade 2-3, stage iiic endometrioid ovarian cancer was optimally debulked and received 6 cycles of intravenous paclitaxel and intraperitoneal cisplatin-paclitaxel.
  • Post chemotherapy, one of several biopsies showed residual disease during the second-look laparoscopy.
  • CASE 2: A 47-year-old woman with a grade 3, stage iiic endometrioid ovarian cancer was optimally debulked and treated with intravenous carboplatin-paclitaxel.
  • Letrozole was administered after the chemotherapy.
  • CONCLUSIONS: Endometrioid ovarian carcinoma may benefit from aromatase inhibitors, especially when the tumour burden is low after primary chemotherapy or when the inhibitor is used as maintenance therapy between chemotherapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151415.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2993449
  • [Keywords] NOTNLM ; Aromatase inhibitor / endometrioid ovarian cancer / letrozole / maintenance therapy / recurrent ovarian cancer
  •  go-up   go-down


21. Fehr MK, Streich MS: [The validity of chemotherapy in the treatment of endometrial cancer]. Gynakol Geburtshilfliche Rundsch; 2006;46(1-2):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The validity of chemotherapy in the treatment of endometrial cancer].
  • [Transliterated title] Der Stellenwert der Chemotherapie in der Therapie des Endometriumkarzinoms.
  • Endometrial cancer is a heterogeneous tumour with two types which can be distinguished clinically, histologically and pathogenetically:the classical endometrioid cancer (type 1) with a good prognosis and the aggressive histological type 2 with a poor prognosis and early metastatic spread.
  • The most active cytotoxic drugs in advanced or metastatic endometrial cancer are the anthracyclines, the platinum salts and the taxanes.
  • In most studies, combination chemotherapy is superior to monotherapy in terms of response rates.
  • In the last few years there is growing evidence that chemotherapy can prolong overall survival in metastatic endometrial cancer and that adjuvant chemotherapy can reduce recurrence rates in high-risk situations.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrium / pathology. Female. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Randomized Controlled Trials as Topic. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452818.001).
  • [ISSN] 1018-8843
  • [Journal-full-title] Gynäkologisch-geburtshilfliche Rundschau
  • [ISO-abbreviation] Gynakol Geburtshilfliche Rundsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 30
  •  go-up   go-down


22. Agrawal A, Nation J, Ghatage P, Chu P, Ross S, Magliocco A: Malignant chest wall endometriosis: a case report and literature review. J Obstet Gynaecol Can; 2009 Jun;31(6):538-541
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Endometriosis usually affects women in their reproductive years.
  • CASE: A 47-year-old woman who had undergone hysterectomy and bilateral salpingo-oophorectomy for endometriosis presented four years after surgery with a well-differentiated endometrioid adenocarcinoma arising in the background of endometriosis in the right chest wall.
  • The tumour was resected, and the patient received six courses of adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Transformation, Neoplastic. Thoracic Neoplasms / pathology. Thoracic Wall / pathology
  • [MeSH-minor] Endometriosis / pathology. Endometriosis / surgery. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646320.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Vandenput I, Van Calster B, Capoen A, Leunen K, Berteloot P, Neven P, Moerman P, Vergote I, Amant F: Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer; 2009 Jul 21;101(2):244-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
  • BACKGROUND: To investigate the value of neoadjuvant chemotherapy (NACT), followed by interval debulking surgery (IDS), in endometrial cancer with transperitoneal spread (stage IV).
  • Efficacy was determined according to the Response Evaluation Criteria in Solid Tumors, residual tumour at IDS and histopathological assessment of tumour regression.
  • Histopathological subtypes were as follows: serous (90%), clear cell (3%) and endometrioid (6%) carcinoma.
  • A total of 24 patients (80%) had optimal cytoreduction (R <or=1 cm), of whom 22 (92%) were without residual tumour.
  • The median progression-free survival and overall survival times were 13 and 23 months, respectively.Histopathological features of chemoresponse in both uterus and omentum were related to a better PFS (P=0.017, hazard ratio (HR) =0.785) and overall survival (P=0.014, HR=0.707).
  • In particular, the absence of tumour infiltration and necrosis were associated with prognosis.
  • CONCLUSION: The use of NACT resulted in a high rate (80%) of optimal IDS for the treatment of endometrial cancer with transperitoneal spread.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Disease-Free Survival. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Prospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):211-7 [17239941.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):710-8 [17182981.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):160-3 [17490737.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):190-3 [17825394.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):92-9 [11277657.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):466-70 [11906550.001]
  • [Cites] Int J Gynecol Cancer. 2002 Sep-Oct;12(5):454-8 [12366662.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):74-7 [12488296.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):653-8 [15196860.001]
  • [Cites] Gynecol Oncol. 1990 Jun;37(3):327-31 [2351315.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):237-40 [8314145.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):123-7 [8690284.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):56-60 [9345357.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):431-6 [9887245.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):140-4 [10094895.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):461-3 [10366480.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:273-7 [16515603.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):986-90 [16803473.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):926-34 [17397905.001]
  • (PMID = 19568245.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2720217
  •  go-up   go-down


24. Cryns P, Roofthooft NJ, Tjalma WA: Malignant mixed müllerian tumor of the ovary and false negative punctures. Eur J Gynaecol Oncol; 2003;24(1):70-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor of the ovary and false negative punctures.
  • Malignant mixed müllerian tumour (MMMT) of the ovary is a rare and aggressive tumour with a poor prognosis.
  • We present a case of a 57-year-old woman with a large pelvic mass, omental cake, ascites and pleural effusions, clinically highly suspect of an ovarian neoplasm.
  • The latter gave a histopathologic diagnosis of an endometrioid adenocarcinoma of the ovary.
  • However after cytoreductive surgery anatomopathologic examination revealed a malignant mixed müllerian tumour of the ovary with heterologous differentiation.
  • Adjuvant chemotherapy, active against the sarcomatous and the carcinomatous component, was given.
  • If a tumour consists of two components, puncture can miss one, which may lead to undertreatment.
  • [MeSH-major] Adenocarcinoma / pathology. Mixed Tumor, Malignant / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Combined Modality Therapy. Diagnosis, Differential. False Negative Reactions. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12691322.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. D'Angelo E, Prat J: Classification of ovarian carcinomas based on pathology and molecular genetics. Clin Transl Oncol; 2010 Dec;12(12):783-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on light microscopy and molecular genetics, ovarian carcinomas are subdivided into at least five main subtypes that account for over 95% of cases and are inherently different diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, molecular events during oncogenesis, response to chemotherapy and outcome.
  • For successful subtype-specific treatment, reproducible pathological diagnosis of tumour cell type is critical.
  • Recent investigations have also demonstrated that a significant number of cancers traditionally thought to be primary ovarian tumours (particularly serous, endometrioid and clear cell carcinomas) originate in the fallopian tube and the endometrium and involve the ovary secondarily.
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Female. Humans. Neoplasms, Glandular and Epithelial / classification. Neoplasms, Glandular and Epithelial / genetics. Neoplasms, Glandular and Epithelial / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2004 Feb;44(2):109-15 [14764054.001]
  • [Cites] Cancer Res. 1998 May 15;58(10 ):2095-7 [9605750.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):605-19 [16021566.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 [10749912.001]
  • [Cites] BMC Cancer. 2008 Jan 22;8:17 [18208621.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):342-6 [10053105.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1581-6 [9118042.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):139-52 [11812936.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1360-8 [15668893.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Obstet Gynecol. 2002 Jan;99(1):3-10 [11777502.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):469-73 [17765295.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):147-59 [15043303.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1344-7 [9537226.001]
  • [Cites] Obstet Gynecol. 2002 Aug;100(2):281-7 [12151151.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Obstet Gynecol. 2006 Aug;108(2):361-8 [16880307.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Hum Pathol. 2009 Sep;40(9):1213-23 [19552940.001]
  • [Cites] J Pathol. 2007 Feb;211(3):286-95 [17154249.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • (PMID = 21156408.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Ovarian epithelial cancer
  •  go-up   go-down


26. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP: Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology; 2008 Aug;53(2):127-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prolongation of ovarian epithelial cancer survival depends on early detection or improved responses to chemotherapy.
  • The serous carcinogenic sequence in the distal fallopian tube is described and contrasted with lower grade serous tumors based on tumour location, earliest genetic change and ability (or lack of) to undergo terminal (ciliated) differentiation.
  • Ultimately, a clear understanding of tumour origin and the mechanism(s) leading to the earliest phases of the serous and endometrioid carcinogenic sequences may hold the greatest promise for designing prevention strategies and/or developing new therapies.
  • [MeSH-minor] Animals. Female. Humans

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2009 Mar;54(4):494-5 [19309405.001]
  • (PMID = 18298580.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R21 CA124688; United States / NCI NIH HHS / CA / 1P50CA 105009; United States / NCI NIH HHS / CA / K08 CA108748
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 52
  •  go-up   go-down






Advertisement